Lao-Tzu Allan-Blitz,Marcella R Cardoso,Alexandra A Kwiecien et al.
Lao-Tzu Allan-Blitz et al.
Albert C M Ong,Sol Carriazo,Becky Mingyao Ma et al.
Albert C M Ong et al.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of chronic kidney disease, resulting in substantial morbidity and mortality globally. Advances in molecular genetics and deep-phenotype imaging techniques...
Sek Won Kong,In-Hee Lee,Young Cha et al.
Sek Won Kong et al.
Trump claims Venezuela does not meet trafficking standards-but what about the USA? [0.03%]
特纳普宣称委内瑞拉不符合反人口贩卖标准，但是美国呢？
Sonja Ayeb-Karlsson,Tyler Valiquette
Sonja Ayeb-Karlsson
Mervyn Singer,Derek C Angus,Djillali Annane et al.
Mervyn Singer et al.
Sepsis is defined as a dysregulated host response to infection that leads to life-threatening organ dysfunction. The infectious insult triggers a dysregulated immune response that variably activates and suppresses multiple body system funct...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial [0.03%]
一项多国大型非劣效性、开放标签、随机三期试验：每日一次口服Orforglipron与司美格鲁肽在2型糖尿病成人患者中的疗效和安全性（ACHIEVE-3）
Julio Rosenstock,Daisuke Yabe,David Cox et al.
Julio Rosenstock et al.
Background: Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and safety of orforglipron with ...
Impact of adding hormone therapy to postoperative radiotherapy in prostate cancer [0.03%]
前列腺癌术后放疗中添加内分泌治疗的影响分析
Ana M Aparicio,Patrick G Pilié
Ana M Aparicio
Oral GLP-1 receptor agonists: competition for efficacy and tolerability [0.03%]
口服GLP-1受体激动剂：疗效和耐受性的竞争
Michael A Nauck,Michael Horowitz
Michael A Nauck
Language in rare disease: a call for systemic and empathetic action [0.03%]
罕见病的语言问题：呼吁采取系统的、充满同理心的行动
Gareth Baynam,Kym M Boycott,Kirsten Johnson et al.
Gareth Baynam et al.
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis [0.03%]
前列腺癌术后放疗中激素治疗的使用及持续时间：个体患者资料的 Meta 分析
Amar U Kishan,Yilun Sun,Christopher C Parker et al.
Amar U Kishan et al.
Background: Adding hormone therapy to definitive radiotherapy in localised prostate cancer improves overall survival, but whether it similarly improves overall survival in the context of postoperative radiotherapy (PORT) ...